Sustained monomorphic ventricular tachycardia after adenosine infusion

Huemer, Martin; Boldt, Leif‐Hendrik; Rolf, Sascha; Blaschke, Daniel N.; Parwani, Abdul Shokor; Haverkamp, Wilhelm

doi:10.1016/j.ijcard.2007.07.068

Cited by 4 publications

(1 citation statement)

References 8 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…152 Significant tachyarrhythmias have also been encountered in the form of torsades de pointes, sustained VT and VF. [153][154][155][156][157][158][159] The risk of VF may be increased when adenosine is used in stable VT, preexcitation or in patients with a prolonged QT interval. [160][161][162] Several case series highlight the risk of inducing ventricular arrhythmia during fractional flow reserve measurements following intracoronary adenosine administration, suggesting that IV is a safer route or that lower doses are needed.…”

Section: Pro-arrhythmic Effects Of Adenosinementioning

confidence: 99%

Unmasking Adenosine: The Purinergic Signalling Molecule Critical to Arrhythmia Pathophysiology and Management

Matthews

Grace

2020

Arrhythm Electrophysiol Rev

View full text Add to dashboard Cite

Adenosine was identified in 1929 and immediately recognised as having a potential role in therapy for arrhythmia because of its negative chronotropic and dromotropic effects. Adenosine entered mainstream use in the 1980s as a highly effective agent for the termination of supraventricular tachycardia (SVT) involving the atrioventricular node, as well as for its ability to unmask the underlying rhythm in other SVTs. Adenosine has subsequently been found to have applications in interventional electrophysiology. While considered a safe agent because of its short half-life, adenosine may provoke arrhythmias in the form of AF, bradyarrhythmia and ventricular tachyarrhythmia. Adenosine is also associated with bronchospasm, although this may reflect irritant-induced dyspnoea rather than true obstruction. Adenosine is linked to numerous pathologies relevant to arrhythmia predisposition, including heart failure, obesity, ischaemia and the ageing process itself. This article examines 90 years of experience with adenosine in the light of new European Society of Cardiology guidelines for the management of SVT.

show abstract